Goldman Sachs’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.16M | Buy |
1,350,649
+1,356
| +0.1% | +$5.76K | ﹤0.01% | 3888 |
|
|
2025
Q4 | $4.87M | Buy |
1,349,293
+787,036
| +140% | +$3.43M | ﹤0.01% | 3770 |
|
|
2025
Q3 | $2.12M | Buy |
562,257
+63,019
| +13% | +$243K | ﹤0.01% | 4425 |
|
|
2025
Q2 | $1.93M | Buy |
499,238
+108,903
| +28% | +$589K | ﹤0.01% | 4212 |
|
|
2025
Q1 | $1.95M | Sell |
390,335
-135,835
| -26% | -$860K | ﹤0.01% | 4182 |
|
|
2024
Q4 | $3.79M | Sell |
526,170
-406,655
| -44% | -$3.11M | ﹤0.01% | 3730 |
|
|
2024
Q3 | $5.73M | Sell |
932,825
-77,324
| -8% | -$524K | ﹤0.01% | 3225 |
|
|
2024
Q2 | $6.72M | Buy |
1,010,149
+148,734
| +17% | +$1.1M | ﹤0.01% | 2885 |
|
|
2024
Q1 | $8.77M | Buy |
861,415
+337,165
| +64% | +$3.43M | ﹤0.01% | 2589 |
|
|
2023
Q4 | $5.9M | Buy |
524,250
+401,767
| +328% | +$1.68M | ﹤0.01% | 3019 |
|
|
2023
Q3 | $318K | Sell |
122,483
-50,689
| -29% | -$145K | ﹤0.01% | 4873 |
|
|
2023
Q2 | $611K | Sell |
173,172
-681,887
| -80% | -$3.06M | ﹤0.01% | 4631 |
|
|
2023
Q1 | $3.61M | Buy |
855,059
+87,225
| +11% | +$1.04M | ﹤0.01% | 3362 |
|
|
2022
Q4 | $12.6M | Buy |
767,834
+32,090
| +4% | +$360K | ﹤0.01% | 2370 |
|
|
2022
Q3 | $9.39M | Buy |
735,744
+230,988
| +46% | +$3.41M | ﹤0.01% | 2570 |
|
|
2022
Q2 | $5.91M | Sell |
504,756
-224,113
| -31% | -$1.38M | ﹤0.01% | 2985 |
|
|
2022
Q1 | $4.44M | Buy |
728,869
+243,450
| +50% | +$1.79M | ﹤0.01% | 3466 |
|
|
2021
Q4 | $4.45M | Buy |
485,419
+8,614
| +2% | +$91.5K | ﹤0.01% | 3536 |
|
|
2021
Q3 | $5.39M | Buy |
476,805
+454,960
| +2,083% | +$5.53M | ﹤0.01% | 3294 |
|
|
2021
Q2 | $215K | Sell |
21,845
-113,385
| -84% | -$1.55M | ﹤0.01% | 5699 |
|
|
2021
Q1 | $1.91M | Buy |
135,230
+88,448
| +189% | +$1.43M | ﹤0.01% | 4030 |
|
|
2020
Q4 | $528K | Sell |
46,782
-8,598
| -16% | -$101K | ﹤0.01% | 4573 |
|
|
2020
Q3 | $731K | Buy |
55,380
+16,994
| +44% | +$340K | ﹤0.01% | 4279 |
|
|
2020
Q2 | $411K | Buy |
+38,386
| New | +$211K | ﹤0.01% | 4467 |
|
|
2017
Q3 | – | Sell |
-1,948
| Closed | -$187K | – | 6637 |
|
|
2017
Q2 | $187K | Buy |
1,948
+1,130
| +138% | +$188K | ﹤0.01% | 5831 |
|
|
2017
Q1 | $199K | Buy |
818
+628
| +331% | +$336K | ﹤0.01% | 5734 |
|
|
2016
Q4 | $185K | Buy |
190
+134
| +239% | +$120K | ﹤0.01% | 5817 |
|
|
2016
Q3 | $49K | Buy |
+56
| New | +$43.9K | ﹤0.01% | 6478 |
|
|
2016
Q1 | – | Sell |
-57
| Closed | -$32K | – | 7063 |
|
|
2015
Q4 | $32K | Buy |
57
+20
| +54% | +$9.97K | ﹤0.01% | 6726 |
|
|
2015
Q3 | $15K | Sell |
37
-7
| -16% | -$3.32K | ﹤0.01% | 7084 |
|
|
2015
Q2 | $24K | Sell |
44
-1
| -2% | -$505 | ﹤0.01% | 7055 |
|
|
2015
Q1 | $22K | Sell |
45
-4
| -8% | -$1.99K | ﹤0.01% | 6887 |
|
|
2014
Q4 | $27K | Buy |
+49
| New | +$25.2K | ﹤0.01% | 6943 |
|
|
2013
Q3 | – | Sell |
-1
| Closed | -$1K | – | 6549 |
|
|
2013
Q2 | $1K | Buy |
+1
| New | +$496 | ﹤0.01% | 6310 |
|
Other funds holding ALT
VCM
VPM
N
Goldman Sachs's ALT Position: Q1 2026 in Review
Goldman Sachs increased its Altimmune (ALT) stake by 0.1% in Q1 2026, buying an estimated $5.76K and bringing the position to 1,350,649 shares worth $4.16M. The position accounts for ﹤0.01% of the portfolio, ranked #3888.
Goldman Sachs first reported a position in ALT in Q2 2013 and has held it in 34 quarters since. The position peaked at $12.6M in Q4 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.
- Goldman Sachs held 1,350,649 shares of Altimmune worth $4.16M as of Q1 2026.
- Goldman Sachs bought 1,356 Altimmune shares in Q1 2026, an estimated $5.76K.
- Altimmune made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3888 holding.
- Goldman Sachs first reported a position in Altimmune in Q2 2013 and has held it in 34 quarters since.
- Goldman Sachs's Altimmune position peaked at $12.6M in Q4 2022.
- 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.